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Introduction
Investigations devoted to the study of biochemical 
aspects of periodontitis and remedies for its treatment have 
particular importance for medical science [1]. Research in 
recent years towards the study of etiologies and physiopa-
thology of periodontitis, have led to various changes in the 
homeostatic system and disease evolution, programs had been 
developed and diagnostic tests to determine disease trends 
and forecast, new treatment programs were proposed [3, 4, 
10, 11]. At the current level of knowledge, however, many 
issues remain undecided or still insufficiently elucidated in 
this disease. Far from being solved are the complex problems 
of diagnosis of homeostatic changes, the development of new 
therapeutic programs and optimizing methods of the charac-
teristic metabolic changes of such diseases. Currently there 
are attempts to find effective remedies with osteoregenerative 
effect in experimental osteoporosis [7].
Bone is a dynamic system which is permanently renewed 
during a person’s lifetime by the remodeling process: osteolysis 
– bone resorption and osteogenesis – bone formation. The 
aforementioned processes take place in certain bone structures 
called basic multicellular units (BMU). Bone mass depends 
on the balance between processes of bone resorption and 
formation by the number of ВМU activated in a given time 
interval and systems bone segment. Biochemical markers of 
bone metabolism can provide information about the intensity 
of metabolic processes in bone tissue and in particular, the 
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Пиколинат цинка обладает выраженными остеорегенеративными свойствами, которые проявляются стимулированием активности 
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activation frequency of ВМU.
Alkaline phosphatase, which is secreted by the os-
teoblasts and catalyses the hydrolysis of organic esters of 
phosphoric acid, is currently the only enzyme with practical 
significance for bone tissue pathology. In blood serum three 
isoenzymes of alkaline phosphatase are present: liver, kidney 
and bone. Bone isoenzymes differ from the hepatic alkaline 
phosphatase by a greater susceptibility to heat inactivation. 
Bone thermo stable alkaline phosphatase is an enzyme located 
on the osteoblasts membrane. 
Acid phosphatases are a group of lyzosomal enzymes 
which hydrolyze monophosphoric esters in acid medium. 
They are present in bone tissue, macrophages, platelets, red 
blood cells, spleen etc. Bone acid phosphatase isoenzyme 
detection is based on its property to preserve activity in the 
presence of tartrate. Tartrate resistant acid phosphatase is re-
leased by osteoclasts during the adhesion with the brush edge 
of the cell to the bone, when a number of lyzosomal enzymes 
are eliminated, which degrade organic components of bone. 
Calcium phosphate salts play an important role in bone 
metabolism. They represent 95% of the inorganic composition 
of bone. They are presented in a form similar to hydroxiappa-
tite – a mineral frequently found in nature – and therefore are 
considered to be salts of hydroxiappatite type (hydroxiappatite 
like salts) [2, 4]. In conjunction with these two basic elements 
of bone tissue – calcium and phosphate, zinc is also present 
which increases inorganic phosphate uptake. Microelements 
show significant action on the state of bone, activating alkaline 
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phosphatase, primary osteogenetic enzyme [8, 10]. Also, zinc 
manifests stabilizing action on the cell membranes preventing 
the release of hydrolytic enzymes, which control bone tissue 
degeneration speed [7, 11].
Coming from the above, the purpose of this study 
was to assess changes of the activity of key markers of bone 
metabolism – termolabile alkaline phosphatase and tartrate 
resistant acid phosphatase, as well as some indices of mineral 
metabolism (Ca, P, Fe, Zn) in patients with periodontitis and 
the opportunity to introduce Zn picolinate into periodontitis 
treatment protocols as a pathogenic remedy for the correction 
of metabolic disturbances specific for the condition.
Material and methods
Research trials were conducted in the Clinic of the Pediatric 
Dentistry Department of USMF “Nicolae Testemitanu”.
To research the influence of zinc picolinate on main bone 
metabolism markers – termolabile alkaline phosphatase (FAT) 
and tartrate resistant acid phosphatase (FATR) and indices of 
mineral metabolism in patients with periodontitis, 27 patients 
with chronic generalized periodontitis of moderate severity 
and impairment were selected. Participants were aged between 
30 and 70 years with disease duration greater than 10 years. 
Treatment (standard treatment) of chronic generalized peri-
odontitis was performed according to contemporary protocols 
including antimicrobial remedies, anti-inflammatory drugs, 
antiseptics and orthodontic treatment with application of 
titanium implants (after professional oral hygiene, curettage 
of periodontal bags, selective polishing etc.) [8, 9].
Patients were divided into 2 groups:
I – patients (12) which have received traditional complex 
treatment (standard treatment);
II – patients (15) undergoing standard treatment includ-
ing zinc picolinate (study group). 
Total alkaline phosphatase and total acid phosphatase 
activities were determined using standard sets of reagents 
(Elitech, France). The method is based on the ability of the 
enzyme to hydrolyze p-nitrofenilphosphate to p-nitrophenol, 
which is determined using spectrophotometrically. 
Bone termolabile alkaline phosphatase is calculated by 
determining the difference between total alkaline phosphatase 
activity and the thermo stable alkaline phosphatase activity. 
To determine thermo stable alkaline phosphatase, the serum 
is subject to a preincubation heating at 56 C° for 10 minutes. 
The assay for the bone tartrate-resistant acid phosphatase 
activity, is the same as for the thermo stable alkaline phos-
phatase, with the exception that it takes place in acid medium 
in the presence of the inhibitor – potassium-sodium tartrate 
(1mol/l concentration).
Assays for total calcium, inorganic phosphate, iron and 
zinc levels in blood serum were performed by photometric 
method using standard sets of reagents (Elitech, France).
Results and discussion
The study showed reduced activity of total alkaline phos-
phatase and its termolabile isoenzyme in the blood serum in 
patients with periodontitis (Table 1). Thus, until the beginning 
of the treatment both total alkaline phosphatase activity and 
the termolabile alkaline phosphatase in blood serum were 
reduced by 24% and 31% (p < 0,05) respectively in comparison 
with control levels. In patients undergoing standard treatment 
including zinc picolinate (study group), there is a continuous 
increase in the activity of mentioned enzymes up to the levels 
in the control group, which were higher than the initial values. 
Thus termolabile alkaline phosphatase activity after 6 and 12 
months of treatment increased by 66% and 54% respectively 
from the initial indices at the beginning of the treatment. 
Increased levels of termolabile alkaline phosphatase activity 
table 1
Dynamics of biochemical markers of bone tissue metabolism in blood serum of the patients  
with periodontitis with the application of titanium implants and zinc picolinate administration
Research  
conditions nr.
Total alkaline  
phosphatase (UI/l)
Termolabile  
alkaline phosphatase
 (UI/l)
Total acid  
phosphatase (UI/l)
Tartrate-rezistent acid 
phosphatase (UI/l)
K
ration
control 20 283,9 ± 20,7 (100 %) 17,12 ±1,64(100 %)
1,02 ±0,16 
(100 %)
0,83 ± 0,06
(100 %) 20,6
standard treatment
Baseline 12 215,8 ± 12,6* (76 %)
11,75 ±1,40*
(69 %)
0,89 ±0,12 
(87 %)
0,66 ± 0,07
(80 %) 17,8
6 months 8 243,2 ± 25,3 (86 %)
13,90 ± 1,23 
 (81 %)
0,95 ± 0,81 
 (93 %)
0,81 ± 0,08 
 (98 %) 17,2
12 months 6 249,8±27,4(88 %)
12,84±1,36
(75 %) 1,05±0,78 (103 %)
0,85±0,09
(102 %) 15,1
standard treatment + zinc picolinate
Baseline 15 213,6 ± 16,8* (75 %)
11,80 ±1,10*
(69 %)
0,93 ±0,12
(91 %)
0,71 ± 0,08
(86 %) 16,6
6 months 13 354,2 ± 26,7# (125 %)
21,9 ± 1,23*# 
 (128 %)
0,79 ± 0,08 
 (77 %)
0,57 ± 0,07* 
 (69 %) 38,4
12 months 8 329,8±28,6# (116 %) 20,14±1,81#(118 %)
0,82±0,074 
(80 %)
0,64±0,08
(77 %) 31,5
Note: N – number of patients; * – reliability in comparison with control group (p <0.05); # – reliability in comparison with baseline values 
(p < 0,05) K – the ratio between the activities of termolabile alkaline phosphatase and tartrate resistant acid phosphatase.
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– the osteogenesis marker, revealed the stimulating action 
of zinc picolinate on osteoregeneration, associated with the 
formation or repairing of bone.
The results show a statistically inconclusive increase 
of the activity of total alkaline phosphatase and termolabile 
alkaline phosphatase in the blood serum in the dynamic sur-
veillance of patients who received standard treatment without 
zinc picolinate, which attests a weak osteoblast (odontoblast) 
reaction. However, total acid phosphatase activity and tartrate 
resistant acid phosphatase – osteodestruction marker, de-
creases insignificantly in all groups compared with baseline 
and control. 
Practically, the acid phosphatase present in osteoclasts 
does not undergo changes in patients with periodontitis, while 
zinc picolinate has been shown to noticeably reduce enzyme 
activity by 31% (p < 0,05) compared to the reference values 
of the control group. Compared to the control a statistical 
inconclusive reduction of enzyme activity is observed under 
the influence of standard medication. The obtained data 
indicates the stimulating effect on bone remodeling by sup-
pressing the osteoclastic activity caused by zinc picolinate 
administration. At the same time, there is a reduction in the 
ratio of the activities of termolabile alkaline phosphatase and 
tartrate resistant acid phosphatase which, increases during 
the treatment with the zinc picolinate, revealing an increase 
in bone formation. 
The results of the study of mineral metabolism indices 
are reflected in the statistics of Table 2. 
The concentration of total calcium in blood serum in 
patients with periodontitis at the initial stage of research does 
not undergo significant changes compared with the control 
group. After the administration of zinc picolinate medication, 
calcium levels are maintained at the reference values. Standard 
treatment does not cause statistically reliable changes of the 
nominated index. 
Also, there is initially a weak trend of reduction of the 
content of inorganic phosphate in the blood serum in patients 
with periodontitis. Medication with zinc picolinate produced 
some changes in the nominated index, thus the period of 6 
months of the pathologic process is noted to increase the 
phosphate content by 12% (p > 0,5) from baseline whereas 
standard treatment has not been shown to influence it.
The serum iron level in periodontitis decreases by 23-
26% (p < 0,05) compared with the control values. Standard 
treatment at all stages of research has shown a rising trend of 
iron content, but these changes are not statistically reliable. 
Medication with zinc picolinate prevents a decrease in the 
index in patients with periodontitis, which is demonstrated 
by the fact that at 6 and 12 months of the pathologic process 
the levels of serum iron in the specific group are maintained 
at amounts that exceeded the baseline and were statistically 
relevant. 
The research carried out shows a statistically suggestive 
depression of zinc content in blood serum of patients with 
periodontitis comparing with the control group. The addi-
tion of zinc picolinate determined an increase in the content 
of zinc, which exceeded by 43% baseline values by 43% and 
control group level by 30% (p < 0,05). Standard treatment 
induces the restoration of serum zinc levels to that determined 
in the control group.
Conclusions
1. In general, chronic periodontitis disorders of bone 
remodeling processes are manifested by decreased activity 
of termolabile alkaline phosphatase and of the ratio between 
the activities of termolabile alkaline phosphatase activity and 
tartrate resistant acid phosphatase, while the activity of tartrate 
resistant acid phosphatase suffers no changes. 
2. Zn picolinate possesses pronounced osteoregen-
erative properties which are manifested by stimulating bone 
table 2
the concentration of total calcium, inorganic phosphate, iron and zinc in blood serum in patients  
with periodontitis with the application of titanium implants and zinc picolinate administration
Research conditions N Total calcium(mmol/l)
Anorganic phosphate
(mmol/l)
Iron
(mmol//l)
Zinc
(mmol//l)
Control 20 2,56±0,23(100%)
1,71±0,12
(100%)
21,43±0,23
(100%)
18,50±0,16
(100%)
Standard treatment 
Baseline 12 2,53±0,37(99%)
1,58±0,18
(92%)
16,54±0,26*
(77%)
16,12±0,39*
(87%)
6 months 10 2,55±0,17(100%)
1,66±0,27
(97%)
19,67±0,28
(92%)
17,89±0,81
(97%)
12 months 6 2,52±0,25(98%)
1,70±0,25
(99%)
21,13±0,31
(99%)
18,37±0,42
(99%)
standard treatment + zinc picolinate
Baseline 15 2,51±0,26(98%)
1,56±0,18
(91%)
15,81±0,36*
(74%)
16,92±0,26*
(91%)
6 months 13 2,64±0,17(103%)
1,75±0,20
(102%)
22,54±0,38#
(105%)
24,17±0,61*#
(130%)
12 months 8 2,57±0,27(100%)
1,72±0,26
(100%)
23,19±0,40#
(108%)
23,41±0,27*#
(127%)
Note: N - Number of patients; * - reliability in comparison with control group (p < 0,05); # - reliability in comparison with baseline values 
(p < 0,05).
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termolabile alkaline phosphatase activity and reduction of 
functional level of tartrate resistant acid phosphatase in peri-
odontitis. 
3. The study revealed insignificant disturbances of 
calcium phosphate metabolism in periodontitis, with con-
tents of iron and zinc decreased only in advanced stages of 
periodontitis. 
4. Zn picolinate has the ability to modulate the pro-
cesses of bone remodeling and shows a favorable effect on 
mineral metabolism changes caused by periodontitis. 
5. The research carried out, confirms the prospective 
use of zinc picolinate as an effective remedy for correction of 
metabolic disturbances caused by periodontitis. 
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Структурно-функциональные изменения сердечно-сосудистой 
системы у больных хронической обструктивной болезнью легких
Chikh Ahmad mahmoud
Кафедра внутренних болезней № 6, ГУМФ им. Н. A. Тестемицану
Morpho-Functional Changes of the Cardio-Vascular System in Patients with Chronic Obstructive Pulmonary Disease
The morpho-functional changes of the cardio-vascular system were studied in 75 patients with chronic obstructive pulmonary disease. 
In Holter-monitoring ventricular extrasystoles (VES) were registered with almost the same frequency in all three stages of COPD. Grouped 
supraventricular extrasystoles (SVES) were found in 6.9% of the cases of COPD in stage 1, in 14% in stage 2, and in 33.3% in stage 3 COPD. 
Myocardial ischemia was diagnosed in 32 patients, 42.6% of the total number of the study group. In stage 1 painful ischemia was found in 17.2% 
and painless myocardial ischemia in 20.6%, in stage 2 – 14.2% and 32.1%, and in stage 3 – 14.2 and 32.1%, more often in younger persons. 
Key words: chronic obstructive pulmonary disease, myocardial ischemia.
Schimbările morfofuncţionale ale sistemului cardiovascular la bolnavii cu bronhopneumopatie obstructivă cronică 
Schimbările morfofuncţionale ale sistemului cardiovascular au fost studiate la 75 de bolnavi cu bronhopneumopatie obstructivă cronică. 
Prin intermediul Holter-monitorizării, s-au înregistrat extrasistole ventriculare (ESV) practic cu aceeaşi frecvenţă în toate 3 stadii ale BPOC. 
Extrasistole supraventriculare (ESSV) în grup s-au depistat la 6,9% din cazuri cu I stadiu al BPOC, la 14% – cu al II stadiu, la 33,3% – cu al III 
stadiu al bolii. La 32 de pacienţi s-a depistat ischemia miocardului, ceea ce constituie 42,6% din numărul de bolnavi investigaţi. Ischemia doloră 
s-a depistat la 17,2%, asimptomatică – la 20,6% dintre bolnavii cu I stadiu, la 14,2% şi 32,1% – cu al II stadiu, la 14,2% şi 32,1% – cu al III stadiu 
al bolii respectiv, şi mai des se înregistra la persoanele mai tinere. 
Cuvinte-cheie: bronhopneumopatie obstructivă cronică, extrasistolii ventriculare şi supraventriculare, ischemia miocardului. 
